A novel validated LC method for quantitation of lopinavir in bulk drug and pharmaceutical formulation in the presence of its potential impurities and degradation products.
A simple isocratic liquid chromatographic method was developed for determination of lopinavir from its related impurities and assay for the first time. This method involves the use of a C(8) (Symmetry Shield RP8, 150 x 4.6 mm, 5 microm) column. The method was validated over the range of limit of quantitation (LOQ) to 120% of impurity specification limit and LOQ to 150% of working concentration for assay. The mobile phase consisted of a mixture of 50 mM of potassium phosphate buffer, acetonitrile and methanol in the ratio of 40:50:10. The flow rate was set at 1.0 mL/min with UV detection monitored at 210 nm. The drug was subjected to stress conditions of hydrolysis, oxidation, photolysis and thermal degradation. The developed method was validated for linearity, range, precision, accuracy and specificity. This method was successfully applied for content determination of lopinavir in pharmaceutical formulations. The method can be conveniently used in a quality control laboratory for routine analysis for assay and related substances as well for the evaluation of stability samples of bulk drugs and pharmaceutical formulations.
Seshachalam
U
U
Quality Assurance, Matrix Laboratories Limited, 1-1-151/1, Sairam Towers, Alexander Road, Secunderabad, Andhra Pradesh 500 003, India. chalam_us@rediffmail.com
Haribabu
B
B
Chandrasekhar
Kb
K
D017320:HIV Protease Inhibitors / Q000032:analysis*; D061466:Lopinavir; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011744:Pyrimidinones / Q000032:analysis*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013056:Spectrophotometry, Ultraviolet
D017320:HIV Protease Inhibitors; D004364:Pharmaceutical Preparations; D011744:Pyrimidinones; D061466:Lopinavir